ClinicalTrials.gg
RecruitingNCT06698601BlueVantageUpdated Oct 1, 2026

Wild Blueberries in Colitis

An interventional study of blueberry-rich diet and Control diet in Ulcerative Colitis (UC) and Crohn Disease (CD), sponsored by Universität Duisburg-Essen. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Universität Duisburg-Essen · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Oct 1, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 243 studies in Colitis, Ulcerative with a site in Germany — 29 open to participants now, 62 under way, 26 of them phase 3. Colitis, Ulcerative · Germany.

Planned enrollment
157th of 202
60 · median 179
Started
2024
with 14 others
No phase
16 of 243
2 open now
Primary completion
2028-01
later than 37 of 61 live
Registered
218th of 243
by date

Among the 243 studies in Colitis, Ulcerative with a site in Germany, this one is the 157th largest by planned enrollment of the 202 interventional ones that give a count, is one of 15 that started in 2024, is one of 16 with no phase, reaches primary completion later than 37 of the 61 other live ones, and was the 218th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

29 of the 243 studies in Colitis, Ulcerative with a site in Germany are open now. Recruiting first, the newest first:

23 more — sign in →

All 29 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 243 studies in Colitis, Ulcerative with a site in Germany, or all of them as a file.
02

Study summary

The goal of this exploratory, prospective, monocentric randomized crossover study is to investigate the influence of a blueberry-rich diet compared to a blueberry-poor diet on the microbiome, the intestinal barrier and the inflammatory process in IBD patients with chronic colitis.

The main question the study aims to answer is:

  • Does a diet rich in blueberries compared to a diet low in blueberries have an influence on disease activity, intestinal inflammation and symptoms in IBD patients with chronic colitis?

Ulcerative Colitis (UC) and Crohn's disease (MC) patients are recruited during an inpatient stay at the Clinic for Internal and Integrative Medicine in Bamberg, Germany. During their routine inpatient stay, patients are treated by an interdisciplinary team using a comprehensive multimodal integrative inpatient therapy concept that combines conventional medicine with a wide range of integrative non-pharmacological treatments, phytotherapy, lifestyle-modification and nutritional therapy. During this time, it is verified whether the patients can participate in the study.

The study consists of two study arms, which are conducted in a cross-over design:

  • Intervention arm: in this study arm, participants receive 12 weeks of blueberry therapy in addition to the regular two weeks of inpatient care at the Clinic for Internal and Integrative Medicine in Bamberg. The blueberry therapy includes drinking around 35 g of blueberry powder stirred into water once a day for 12 weeks.
  • Control arm: in this study arm, participants receive the standard therapy (integrative medical therapy concept described above) during the regular two-week hospital stay. There is no additional blueberry intake.

Due to the crossover study design, all participants undergo both study arms. This means that each participant takes the supplementary blueberry powder (intervention) for a period of 3 months and the control therapy for 3 months. The order in which the participants receive the forms of therapy is determined randomly. Thus, half of the study participants start the supplementary blueberry intake directly after the inpatient stay, the second half three months later (cross-over principle).

UC and MC patients will:

  • initially receive a clinically indicated colonoscopy with confocal laser endomicroscopy (CLE) during their routine inpatient stay at the Clinic for Internal and Integrative Medicine in Bamberg
  • return to the clinic for an optional sigmoidoscopy with CLE after 12 and 24 weeks
  • answer questionnaires at study start as well as after 12 and 24 weeks to analyze their quality of life, the severity of their symptoms and their disease activity
  • give samples of blood, urine, stool and bile fluid as well as intestinal biopsies during the colonoscopy/sigmoidoscopy at study start as well as after 12 and 24 weeks
  • document their intake of blueberry powder as well as their symptoms and stool frequencies in a diary throughout the study participation
Read the detailed description

Background:

Chronic inflammatory bowel disease (IBD) affects the lives of millions of people worldwide due to recurrent, severe clinical symptoms, potential complications and ongoing medical interventions. The scientific community currently assumes a multicausal pathogenesis in IBD caused by an unfavorable constellation of genetic predisposition, imbalance of pathogenic to symbiotic gut bacteria (dysbiosis) and harmful environmental and lifestyle factors resulting in an excessive immune response.

The intestinal barrier and the microbiome play a key role in maintaining intestinal balance and health. The intestinal barrier protects our body from bacteria, viruses and fungi in the intestinal lumen, while it enables the absorption of nutrients at the same time. In case of a leaky gut, microbial pathogens or their components can enter the deeper cell layers of the intestine and cause acute and long-term inflammatory reactions. The composition of the gut microbiome, i.e. the community of billions of microorganisms living in the gut, has a significant influence on the intestinal barrier and gut health. Beneficial bacteria stabilize the intestinal barrier, strengthen local defenses (mucin and IgA production) and inhibit pro-inflammatory immune reactions and cell death. In contrast, harmful bacteria (pathobionts) disrupt the intestinal barrier, dysregulate cell death and proliferation, which leads to the release of pro-inflammatory signaling substancesand and an immune response causing inflammation.

While previous attempts to develop pharmacological therapies to improve gut barrier function have been unsuccessful, an increasing number of preclinical and clinical trial results highlight the significant impact of a plant-based diet through its modulatory effect on the gut microbiome and the gut barrier in IBD. However, further research is needed to evaluate the role of individual dietary components and complex dietary interventions with anti-inflammatory potential in the prevention and treatment of IBD.

The high levels of prebiotic food components in a plant-rich diet are of particular importance in the treatment of intestinal barrier disorders and the microbiome.

Preclinical and clinical studies highlight the modulatory effect of berries, especially blueberries (Vaccinium myrtillus), on the microbiome, gut health and inflammation due to their richness in prebiotically active polyphenols, flavonoids, anthocyanins and fiber.

However, the influence of blueberries on the intestinal barrier and the microbiome in colitis patients has not yet been investigated. Mechanistically oriented clinical studies are needed to confirm the prebiotic and preclinical findings in the clinic. Through a targeted combination of clinical testing on patients, ex vivo examination of biopsy material and cell biological studies at protein and transcriptome level, it should be possible to develop a comprehensive picture of the influence of a blueberry-rich diet, but also of the underlying pathomechanisms affected.

Aim of the study:

Determination of the influence of a three-month blueberry-rich diet compared to a diet with a low blueberry content on disease activity, intestinal inflammation and symptoms in patients with chronic colitis - initiated as part of a routine inpatient stay during which patients are treated with a comprehensive multimodal integrative therapy concept with dietary changes.

Exploratory study design:

This is an exploratory, prospective, monocentric, randomized, crossover study. 60 IBD patients (n = 30 patients with CD or UC with currently mild to moderate disease activity and n = 30 patients who are currently in remission) are randomized into two groups of 30 subjects each. During a period of 6 months, which follows the inpatient-initiated integrative medical lifestyle modification program, participants undergo two consecutive phases of 3 months each marked by a blueberry-rich and a blueberry-poor diet. Dependent on the study group, half of the study participants start the supplementary blueberry intake directly after the inpatient stay, the second half three months later (cross-over principle).

Before the start of the study (W0), the colon of the participants is initially examined for macroscopic inflammation and for intestinal barrier disorders using confocal laser endomicroscopy as part of regular inpatient care. In order to investigate the influence of the integrative therapy with or without blueberry intake on the intestinal barrier and colonic inflammation, this will be checked after the end of the first 3 months (W12) and after 6 months (W24) in a voluntary control sigmoidoscopy with confocal laser endomicroscopy (CLE) as part of a short inpatient stay.

During the endoscopy, biopsies, bile, stool, urine and blood samples important for the study are taken for examination. These serve to clarify mechanistic relationships between the intestinal barrier function, the microbiome, its metabolic products (metabolome), the immune system, the oxidative stress profile, the antioxidative capacity and the inflammatory process (inflammation markers, immune cells and cytokines). In addition, participants will receive questionnaires at all three time points (W0, W12, W24) to evaluate their IBD-specific and general quality of life, symptoms, disease activity, fatigue and stress levels.

03

Conditions studied

  • Ulcerative Colitis (UC)
  • Crohn Disease (CD)

Keywords

  • ulcerative colitis
  • crohn disease
  • integrative medicine
  • intestinal barrier
  • inflammatory bowel disease
  • confocal laser endomicroscopy
  • wild blueberry
  • bilberry
  • nutrition
  • microbiome
  • inflammation
  • chronic colitis
04

Who can participate

The criteria were revised on the registry on Oct 1, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age > 18 years
  • diagnosis of Crohn's Disease (CD) or Ulcerative Colitis (UC) for at least 6 months with mild to moderate chronic colitis (CD: Harvey-Bradshaw-Index Score 5-16; UC: Partial Mayo Score 2-6 and a Mayo endoscopy subscore of 1-2) or in clinical remission (CD: Harvey-Bradshaw-Index Score 0-4; UC: Partial Mayo Score 0-1 and a Mayo endoscopy subscore of 0)
  • stable IBD-specific medication dosage for at least 3 months [such as thiopurines or biologicals (therapeutic antibodies such as infliximab, adalimumab, vedolizumab, etc.)]
  • inpatient admission to the Department for Internal and Integrative Medicine at the Sozialstiftung Bamberg, Germany for regular treatment
  • clinical indication and performance of an initial colonoscopy with confocal laser endomicroscopy (CLE) or a sigmoidoscopy with CLE, if a colonoscopy has already been performed within the last 6 months and previous findings are available.
  • signed form

Exclusion criteria

Exclusion Criteria:

  • IBD without previously diagnosed inflammation of the colon (e.g. Crohn's Disease without colitis)
  • active flare of IBD with CRP ≥ 100 mg/l
  • artificial bowel outlet in front of the colon (ileostomy)
  • high regular consumption of blueberries (≥ 300 g cultivated blueberries or ≥ 150 g wild blueberries per week) or administration of blueberry therapy in the last 3 months
  • participation in another therapeutic study within the last 30 days
  • Known intolerance to blueberries or their ingredients such as contained anthocyanins or fructose (e.g. fructose malabsorption)
  • presence of known serious infectious diseases e.g. of the liver such as , and C infection
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention group

    wild blueberry

    Dietary Supplement: blueberry-rich diet

  • Other
    Control group

    No wild blueberry

    Other: Control diet

Interventions

  • Dietary supplementblueberry-rich diet

    The study participants follow a diet rich in blueberries for 12 weeks based on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg. Participants will drink approximately 35g of a powder made from wild, freeze-dried blueberries containing 780mg of anthocyanines stirred in a glas of water every morning for a period of 12 weeks.

  • OtherControl diet

    The study participants will focus on the nutritional therapy and the integrative medical concept taught during their inpatient stay at the clinic for internal and integrative medicine in Bamberg. Participants will receive no additional blueberry treatment.

06

What researchers measure

Primary outcomes

  1. Improvement of the intestinal inflammation status evaluated via fecal calprotectin levels

    The inflammation status is evaluated through measurement of fecal calprotectin levels in stool samples. This biomarker provides information about the inflammatory status in the intestine and serves as an objective measure of disease activity.

    Time frame: week 0, 12, 24

Secondary outcomes

  1. Improvement of Crohn's disease severity evaluated by Harvey-Bradshaw-Index (HBI)

    The disease severity of CD patients is evaluated via a validated questionnaire that is specific for Crohn's Disease (Harvey-Bradshaw-Index): The HBI was designed as a simplified version of the CDAI to enable systematic collection of clinical data on Crohn's disease and is used to assess the degree of illness in individuals with Crohn's disease. The index considers five, exclusively clinical parameters. A specific score is assigned for each parameter. To assess disease activity, the sum score is formed from questions on general condition, abdominal pain, number of unformed bowel movements per day, abdominal resistance and complications. The highest possible sum is 30 points and indicates a severe course of disease. A lower sum than 5 points indicates a clinical remission.

    Time frame: week 0, 12, 24

  2. Improvement of ulcerative colitis disease severity evaluated by MAYO-Score

    The disease severity of UC patients is evaluated via a validated questionnaire that is specific for ulcerative colitis (MAYO-Score): The Mayo Score is the most commonly used scoring system for UC in clinical trials and routine practice. It was developed to standardize the severity of a patient's UC symptoms, which is particularly helpful to assess response to treatment over time. For this study, the partial MAYO-Score, which comprises only the non-invasive components of the full Mayo score, as well as the endoscopic subscore are applied. The partial MAYO-Score considers three clinical parameters, each of which is assigned a score from 0 to 3 leading to a maximum score of 9 points. Clinical response is defined as a decrease of at least 2 points. The partial MAYO-Score in combination with the endoscopic subscore are used to assess the patients' disease activity.

    Time frame: week 0, 12, 24

  3. Evaluation of IBD-SI (Inflammatory Bowel Disease Symptom Inventory)

    The IBD-SI combines items from existing clinician-rated or diary-format inventories. After factor analysis, 38 items were retained on 5 subscales: bowel symptoms, abdominal discomfort, fatigue, bowel complications, and systemic complications. A total score as well as subscale scores will be calculated.

    Time frame: week 0, 12, 24

  4. Evaluation of disease-specific quality of life by IBD-Q (Inflammatory Bowel Disease Questionnaire)

    The IBD-Q is the most frequently used questionnaire for disease-specific quality of life in clinical studies on Crohn's disease. It operationalizes quality of life on 4 dimensions (emotional and social impairment as well as bowel-related and systemic symptoms), in addition to a sum score. Answers are recorded on a 7-point Likert scale. High values mean good, low values a reduced quality of life (1=worst score, 7=best score). The total IBD-Q scale ranges from 32 to 224. A score of ≥ 170 can be considered as normal quality of life.

    Time frame: week 0, 12, 24

  5. Assessment of health-related quality of life with the Short Form 12 Health Survey (SF-12)

    The Short Form 12 Health Survey (SF-12) is a validated tool with 12 questions for the general assessment of the physical and mental health status of patients that is widely used in clinical studies. It is the shorter version of the SF-36 questionnaire. Two scores - one score for the physical component (PCS) and one score for the mental component (MCS) - represent the results. The SF-12 physical scale score represents general health perception, physical functioning, physical role functioning, and pain. The mental health score reflects emotional role functioning, mental well-being, negative affectivity, and social functioning. The questionnaire has already been used in various medical publications in different disciplines due to its wide range of applications. A low total value correlates with a poor quality of life, a higher one with a better one. The values determined are compared with the values of the normal population.

    Time frame: week 0, 12, 24

  6. Assessment of the severity of the fatigue syndrome with the Multidimensional Fatigue Inventory (MFI-20)

    The Multidimensional Fatigue Inventory (MFI) is a 20-item scale designed to evaluate five dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity and mental fatigue. The German validated version is used. A scale from 1 to 7 is used to indicate how aptly certain statements regarding fatigue represent the participants' experiences. Higher total scores correspond with more acute levels of fatigue.

    Time frame: week 0, 12, 24

  7. Assessment of perceived stress using the Perceived Stress Scale (PSS-10)

    The Perceived Stress Scale (PSS-10) is a well-established self-report scale and an international standard instrument for measuring perceived stress. The ten questions ask about feelings and thoughts during the last month. In each case, respondents are asked how often they felt a certain way on a five-point scale from 'never' to 'very often'. The PSS score is obtained by summing across all items after responses to the four positively stated items have been reversed. Higher scores indicate higher levels of perceived stress.

    Time frame: week 0, 12, 24

  8. Assessment of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS)

    Anxiety and depression are measured using the Hospital Anxiety and Depression Scale (HADS). The HADS was developed specifically for physically ill patients in clinical settings. The questionnaire contains 14 items: 7 on the anxiety and 7 on the depression scales. The sum values of the HADS-A (anxiety) and HADS-D (depression) scales lie in the 0-21 range, with higher values indicating a stronger manifestation of anxiety/depressiveness. The German validated version is used.

    Time frame: week 0, 12, 24

  9. Assessment of food-related quality of life using the FR-QoL-29 questionnaire

    A validated questionnaire for the systematic assessment of food-related quality of life (FR-QoL) in IBD patients is used to assess psychosocial factors in connection with eating and drinking, such as enjoying food, managing restrictions, and maintaining social relationships. The FR-QoL-29, which contains 29 items, each scored on a 5-point Likert scale (1 = strongly agree; 2 = agree; 3 = neither agree nor disagree; 4 = disagree; 5 = strongly disagree), with 4 questions reversed for scoring. Scores are summed, with a total possible score ranging from 29 to 145, where higher scores reflect a greater FR-QoL.

    Time frame: week 0, 12, 24

  10. Assessment of frequency of consumption and usual portion sizes of particular food groups using the DEGS-Food Frequency Questionnaire

    A food frequency questionnaire (FFQ) is used to determine the frequency of consumption and usual portion sizes of a total of 53 food groups consumed in the last four weeks. The dietary questionnaire was developed and validated for the use in the German Health Examination Survey for Adults 2008-2011 (DEGS). In this study it is used to assess whether the participants' dietary habits change throughout the study and whether they apply the diet taught during nutritional therapy at the inpatient stay at the clinic for internal and integrative medicine in Bamberg.

    Time frame: week 0, 4, 8, 12, 16, 20, 24

  11. Patient Diary

    Over the course of the study, the participants keep a diary in which they document their daily blueberry intake and symptoms to enable the evaluation of their compliance and their tolerance of the blueberry powder.

    Time frame: week 0 to week 24

  12. Colonoscopy/Sigmoidoscopy with confocal laser endomicroscopy (CLE)

    At week 0, participants undergo a colonoscopy with confocal laser endomicroscopy (CLE) (or a sigmoidoscopy with CLE in case a colonoscopy has already been performed within the last six months and the previous findings are available) when clinically indicated as part of their inpatient care. Thereby, the inflammatory status and the intestinal barrier is routinely analyzed. Participants return for a voluntary colonoscopy or sigmoidoscopy at week 12 and week 24. Confocal laser endomicroscopy (CLE, Cellvizio System from Mauna Kea Technology) is the first technology that enables live characterization of the intestinal mucosa and barrier integrity at the cellular level during endoscopy at up to 1000x magnification, allowing local intestinal barrier disorders to be identified and targeted biopsies to be taken. This combined examination of endoscopy and CLE thus enables a comprehensive assessment of the intestinal mucosa on a macroscopic, microscopic and functional level in real time.

    Time frame: week 0, 12, 24

  13. Histopathological analysis of ileo-colorectal biopsies

    Intestinal biopsies, which are routinely taken during colonoscopy/sigmoidoscopy, are processed for histopathological analysis of the mucosal and epithelial structure as well as of the immune cell compartment (H\&E staining).

    Time frame: week 0, 12, 24

  14. Immunohistochemical analysis of ileo-colorectal biopsies

    Intestinal biopsies, which are routinely taken during ileocolonoscopy, are stained using immunohistochemistry and examined for the expression of specific marker proteins. For example, the intestinal barrier will be examined by immunohistochemical analysis of the tight junction marker proteins occludin and claudin-2 or the migration of specific immune cells such as T-lymphocytes using CD3 staining.

    Time frame: week 0, 12, 24

  15. Gene expression analysis of ileo-colorectal biopsies

    Intestinal biopsies taken in addition to those routinely taken during ileocolonoscopy are used for transcriptional analysis by q-PCR to study the gene expression of particular immune cell or inflammatory marker proteins as well as tight junction proteins.

    Time frame: week 0, 12, 24

  16. Evaluation of the systemic inflammatory status by analysis of serum-cytokine concentrations

    To evaluate the systemic inflammatory status, the level of various cytokines such as IL-1β, IL-6, IL-8, IL-10, TNF, IFN-γ, IL-17or IL-4 is analyzed in the serum.

    Time frame: week 0, 12, 24

  17. Complete blood count

    A complete blood count including iron status and liver markers is made. It provides information about the number and type of immune cells. In combination with the general inflammatory markers C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), the complete blood count allows conclusions about the presence and extent of systemic inflammation as well as the disease activity. Checking the iron status and liver markers can provide indications of IBD-associated complications such as anemia and liver dysfunction.

    Time frame: week 0, 12, 24

  18. C-reactive protein (CRP) in the blood

    The concentration of the inflammation marker CRP is measured in the blood.

    Time frame: week 0, 12, 24

  19. Erythrocyte Sedimentation Rate (ESR)

    Determination of the ESR of the blood.

    Time frame: week 0, 12, 24

  20. Analysis of inflammatory markers in the stool

    Besides Calprotectin, also the concentrations of other inflammatory markers such as Lactoferrin and PMN-Elastase are analyzed in the stool to evaluate the intestinal inflammation status quantitatively.

    Time frame: week 0, 12, 24

  21. Analysis of fecal biomarkers to evaluate the integrity of the intestinal barrier

    The concentrations of fecal biomarkers such as Zonulin or α-1-Antitrypsin are determined to quantitatively evaluate the integrity of the intestinal barrier.

    Time frame: week 0, 12, 24

  22. Determination of the I-FABP concentration in the serum

    The I-FABP concentration is measured in serum samples to evaluate the intestinal permeability. I-FABP is a protein exclusively found in intestinal epithelial cells. If the intestinal epithelium is damaged, I-FABP is released into the circulation and can be measured in the serum. Therefore, I-FABP serum levels are a valid biomarker for intestinal permeability in coeliac disease, wheat sensitivity and also in inflammatory bowel disease.

    Time frame: week 0, 12, 24

  23. Determination of the fecal β-Defensin concentration

    Fecal concentrations of the antimicrobial peptide β-Defensin are determined in the stool.

    Time frame: week 0, 12, 24

  24. Fecal microbiome analysis

    The fecal microbiome is analyzed in stool samples in order to determine the influence and the prebiotic properties of the blueberry-rich diet on the intestinal microbiome.

    Time frame: week 0, 12, 24

  25. Analysis of fecal metabolites

    Microbial metabolites such as short chain fatty acids (SCFAs) are analyzed in stool samples in order to determine the influence and the prebiotic properties of the blueberry-rich diet on the intestinal microbiome. Prebiotics are nutritional components that promote the growth and activity of beneficial bacterial species. Prebiotics serve as a nutritional basis for these bacteria and promote, for example, their production of SCFAs that act as essential energy substrates for enterocytes and immune cells. These metabolites have been shown to influence immune cell maturation, immune homeostasis, host energy metabolism and the maintenance of mucosal integrity. Therefore, the combined evaluation of microbiome and microbial metabolites in the stool can contribute to a better understanding of the interplay of these factors in the development and treatment of IBD.

    Time frame: week 0, 12 and 24

  26. Metabolite profiling in the urine

    Metabolite profiling is done from urine samples. This can also provide valuable insights into the (dys)regulation of gut microbial metabolism and host-microbe co-metabolism in the context of IBD.

    Time frame: week 0, 12 and 24

  27. Analysis of oxidative stress in the urine

    8-hydroxy-2-deoxyguanosine (8-OHdG) is analyzed in urine samples as a marker for oxidative stress in order to evaluate the antioxidant potential of the blueberry-rich diet. Oxidative stress plays an important role in a variety of chronic inflammatory diseases, including IBD. Oxidative stress describes a disturbance in the balance between the production and accumulation of reactive oxygen species (ROS). ROS are scavenged by the antioxidant system but can oxidize proteins, lipids and DNA in excessive concentrations. Resulting DNA damage is normally repaired and the oxidation products are excreted in the urine. 8-OHdG, a product of DNA guanine residue oxidation by ROS is an established biomarker for oxidative damage to DNA. Blueberries are known for their antioxidant potential. To evaluate the influence of a blueberry-rich diet on oxidative stress and antioxidant potential, 8-OHdG is analyzed in urine samples.

    Time frame: week 0, 12, 24

  28. Analysis of the antioxidant capacity in the serum

    In addition to the evaluation of oxidative stress in the urine, the systemic antioxidant capacity of the blood is analyzed in serum samples as a reduced total antioxidant capacity can reflect the clinical disease activity.

    Time frame: week 0, 12, 24

  29. Analysis of the thiol status in the serum

    The thiol status records the protective, free thiol groups that intercept extracellular radicals and bind toxic metals and pollutants. The thiol status is therefore a parameter of the extracellular protective system. Reduced thiol levels promote oxidative stress and serve as a marker for chronic inflammatory processes.

    Time frame: week 0, 12, 24

  30. Analysis of the peroxidation of lipids in the serum

    The peroxidation of lipids is evaluated in the serum. The determination of lipid peroxides can indicate an imbalance in antioxidant homeostasis. Lipid peroxides are formed by the reaction of free radicals (ROS) with lipid structures, whereby unsaturated fatty acids contained in lipid membranes or lipid vesicles are oxidized. An excess of lipid peroxides is associated with chronic inflammatory processes.

    Time frame: week 0, 12, 24

  31. Analysis of the composition of bile fluid

    In case an esophagogastroduodenoscopy is performed as part of the routine inpatient care, a sample of bile fluid is collected by simple aspiration from the duodenum in order to assess the secretion and composition of bile acids and their metabolites. Bile acids and their metabolites can have a significant impact on gut health in IBD patients. They have the capacity to modulate inflammation, alter the microbiome and affect the intestinal barrier integrity by regulating the expression of tight junction proteins that control the permeability of the gut wall.

    Time frame: week 0, 12, 24

  32. Anamnesis

    Data collected during anamnesis in the course of the routine in-patient stay such as the course of disease or working ability are documented to enable an evaluation of the participants' medical condition and health status.

    Time frame: week 0, 12, 24

  33. Concomitant medication

    Concomitant medication and especially CED-related therapy of the study participants is documented throughout the study.

    Time frame: week 0, 12, 24

  34. Medical history

    Information on concomitant diseases and the medical history of the study participants is routinely collected and recorded in the course of the in-patient stay as well as in the course of the study to evaluate the participants' medical condition and health status.

    Time frame: week 0, 12, 24

  35. Social demographics

    Social demographic aspects are collected in order to describe the patient collective of the study participants.

    Time frame: week 0

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2028, 37 months after the start.

Of 228 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 37 months is close to that.

Counting every sponsor, half of 239 studies reached it within 34 months; a quarter within 15 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: start Sep 2024 → Dec 2024, primary completion Aug 2026 → Jan 2028 and completion Apr 2027 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 21, 2024
StartActual
Dec 5, 2024was Sep 2024
Primary completionEst.
Jan 2028was Aug 2026
CompletionEst.
Jul 2028was Apr 2027
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 24, 2024→Dec 5, 2024
Oct 1, 2026
Primary completion
Aug 2026→Jan 2028
Oct 1, 2026
Study completion
Apr 2027→Jul 2028
Oct 1, 2026
Eligibility
3 inclusion criteria edited; 3 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • Editeddiagnosis of Crohn's Disease (CD) or Ulcerative Colitis (UC) with mild to moderate colitis for at least 6 months with mild to moderate chronic colitis (CD: Harvey-Bradshaw-Index Score 5-16; UC: Partial Mayo Score 2-6 and a Mayo endoscopy subscore of 1-2) or in clinical remission (CD: Harvey-Bradshaw-Index Score 0-4; UC: Partial Mayo Score 0-1 and a Mayo endoscopy subscore of 0)
  • Editedstable IBD-specific medication dosage for at least 3 months [such as 5-aminosalicylates (5-ASA), thiopurines or biologicals (therapeutic antibodies such as infliximab, adalimumab, vedolizumab, etc.)]
  • Editedclinical indication and performance of an initial colonoscopy with confocal laser endomicroscopy (CLE) or a sigmoidoscopy with CLE, if a colonoscopy has already been performed within the last 6 months and previous findings are available.
Exclusion criteria
  • EditedIBD without previously diagnosed inflammation of the colon (e.g. Crohn's Disease without colitis)
  • Removedactive flare of IBD
  • Editedactive flare of IBD with CRP ≥ 100 mg/l
  • EditedKnown intolerance to blueberries or their ingredients such as contained anthocyanins or fructose (e.g. clinically relevant fructose malabsorption)
Oct 1, 2026
Secondary outcomes
2 description edited
What changed in the outcomes
  • DescriptionColonoscopy/Sigmoidoscopy with confocal laser endomicroscopy (CLE): how it is measured was reworded
  • DescriptionImprovement of ulcerative colitis disease severity evaluated by MAYO-Score: how it is measured was reworded
Oct 1, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Sozialstiftung Bamberg · Bamberg, GermanyContact person changed (no phone or email listed)
Oct 1, 2026
Sponsor
Collaborators removed: Universität Duisburg-Essen
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Start date Sep 24, 2024→Dec 5, 2024
    Primary completion Aug 2026→Jan 2028
    Study completion Apr 2027→Jul 2028
    Eligibility 3 inclusion criteria edited; 3 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • Editeddiagnosis of Crohn's Disease (CD) or Ulcerative Colitis (UC) with mild to moderate colitis for at least 6 months with mild to moderate chronic colitis (CD: Harvey-Bradshaw-Index Score 5-16; UC: Partial Mayo Score 2-6 and a Mayo endoscopy subscore of 1-2) or in clinical remission (CD: Harvey-Bradshaw-Index Score 0-4; UC: Partial Mayo Score 0-1 and a Mayo endoscopy subscore of 0)
    • Editedstable IBD-specific medication dosage for at least 3 months [such as 5-aminosalicylates (5-ASA), thiopurines or biologicals (therapeutic antibodies such as infliximab, adalimumab, vedolizumab, etc.)]
    • Editedclinical indication and performance of an initial colonoscopy with confocal laser endomicroscopy (CLE) or a sigmoidoscopy with CLE, if a colonoscopy has already been performed within the last 6 months and previous findings are available.
    Exclusion criteria
    • EditedIBD without previously diagnosed inflammation of the colon (e.g. Crohn's Disease without colitis)
    • Removedactive flare of IBD
    • Editedactive flare of IBD with CRP ≥ 100 mg/l
    • EditedKnown intolerance to blueberries or their ingredients such as contained anthocyanins or fructose (e.g. clinically relevant fructose malabsorption)
    Secondary outcomes 2 description edited
    What changed in the outcomes
    • DescriptionColonoscopy/Sigmoidoscopy with confocal laser endomicroscopy (CLE): how it is measured was reworded
    • DescriptionImprovement of ulcerative colitis disease severity evaluated by MAYO-Score: how it is measured was reworded
    Sponsor Collaborators removed: Universität Duisburg-Essen
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Sozialstiftung Bamberg · Bamberg, GermanyContact person changed (no phone or email listed)
    + 4 other changes: verification date, oversight details, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06698601
Lead sponsor
Universität Duisburg-Essen
Collaborators
German Crohn's and Colitis Association (DCCV e.V.), Wilhelm Doerenkamp Foundation
Responsible party
Jost Langhorst (Univ. Prof. Dr. med, Universität Duisburg-Essen) — Principal investigator
First posted
Nov 21, 2024
Start date
Dec 5, 2024
Primary completion
Jan 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Oct 1, 2026

Study contacts

Angelika Schmalzl, Dr. rer. nat.
Contact
FIGN@sozialstiftung-bamberg.de
0049 951 503 11650
Jost Langhorst, Univ. Prof. Dr. med.
principal investigator · Universität Duisburg-Essen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion